S66 - CEO Presentation to 2021 AGM
STAR COMBO PHARMA LIMITED Annual General Meeting 23 November 2021 CEO Presentation Key Themes FY21 ? Positive operating cash flow of $332K, up from an operating outflow of $1.02M (FY20) ? Negative COVID impact on earnings with $6.3M non-cash asset write-down of Austoyou and Koala Mall ? Construction and upgrade of multimillion dollar manufacturing facilities to increase capacity, $7.3m investment in Smithfield manufacturing facilities on track ? Strong cash position of $17.3M ? Benefiting from macro trends with strong demand for Australian Made health and wellness products Resilience in contract manufacturing division despite COVID headwinds 2 Our people People Safety COVID Our team have demonstrated agility and tenacity in guiding the business through the uncertain COVID environment and have continued to execute on our strategy of becoming Australia’s leading nutraceutical manufacturer. As a manufacturing business, we are dedicated to ensuring we have a safe workplace. The company has in place a comprehensive occupational health and safety program which all staff are required to follow. No safety incident has been reported at Star Combo YTD 2021. A comprehensive COVID safety plan has been implemented at Star Combo. Significant precautions and additional protocols are in place to safeguard the health and wellbeing of our employees. 3 ? Manufacturing Division (OEM and Branded) – OEM division performed ahead of expectations with increasing volume of bulk orders manufactured due to new customers – 76 new customer accounts acquired with the strongest order book in place for 2022 – Through new product development process commercialised 86 new products – Continued expansion into new territories with $1.0M distribution agreement signed with Vietnam based distributer, for supply of Costar products throughout the country – New product launched under Living Healthy Hemp Seed Oil through the Terry White Chemmart network ? Retail Division (online platform business Austoyou.com and Koala Mall retail stores) – Physical retail store was closed in August with all sales transferred online. Only one physical retail store left open – Newly formed customer service team to improve customer retention Business Division Update 4 ? Q1 FY22 Revenue of $5.8M (Q4 FY21 $6.0M) – OEM division performed ahead of expectations – Supply chain limitations, expected to ease as travel restrictions lift – Retail division continues to be impacted by COVID related restrictions ? Q1 FY22 Customer cash receipts of $5.3M ? One off receipt of $0.3M government grant and COVID related financial support ? Development Approval received for the R&D facilities at 165 Woodpark Road, Smithfield ? Expansion and development of manufacturing facilities at 171-177 Woodpark Road, Smithfield on track Q1 FY22 Trading Update 5 6 ? Manufacturing division continues to perform strongly ? A good start in Q1 FY22, production volume increased by 24% when compared with Q1 FY21 - 50 100 150 200 250 Q1 FY21 Remaining FY21 Q1 FY22 Units Manufactured Qty: million Q1 FY21 production volume increased by 24% to Q1 FY22 Increase in production volume Q1 FY22 7 FY21 Achievements Continued growth in contract manufacturing division Operating cash flow positive with $17.3M in cash in bank Construction of multimillion-dollar, manufacturing facilities to increase capacity Contract manufacturing business remains resilient in face of COVID pandemic 2022 Outlook Contract manufacturing sector remains main area of strategic focus – expect immediate and significant growth in 2022 Contract manufacturing outlook remains resilient benefiting from strong macro trends New market development opportunities providing potential for growth Manufacturing upgrade expected to be finalised in 2022 Achievements & Outlook 8 Investor relations i nvestors@ starcombo.com.au THANK YOU The information in this presentation is not a prospectus or other form of disclosure document prepared in accordance with the requirements of the Corporations Act 2001 (Cth) (Corporations Act) and will not be lodged with the Australian Securities and Investments Commission (ASIC). This presentation provides information in summary form and general information regarding Star Combo Pharma Ltd ACN 615 728 375 (Star Combo or the Company) and the proposed placement to sophisticated and professional investors. This presentation contains information, ideas and analysis which are proprietary to Star Combo. By agreeing to receive this information you also agree to respect the confidential nature of this entire presentation. Specifically you agree not to reproduce in any manner any part of the information contained herein without our prior written consent. This presentation is not complete, is intended only as an outline and has been prepared by and issued by Star Combo to assist in informing interested parties about the Company and should not be considered as an offer or invitation to subscribe for or purchase any securities in the Company or as an inducement to make an offer or invitation with respect to those securities. No agreement to subscribe for securities in the Company will be entered into on the basis of this presentation. This presentation is current as at the date on the cover page. The information in this presentation, therefore, remains subject to change. The Company is under no obligation to update the presentation and the information in this presentation remains subject to change by the Company in its absolute discretion and without notice. This presentation may contain forward looking statements. Whilst the Company has no reason to believe that any such statements are either false, misleading or incorrect, it cannot and does not warrant or guarantee that through either the passage of time or actions beyond the control of the company they will not become so. Actual results, performance or achievements could be significantly different from those expressed in, or implied by, these forward-looking statements. Nothing contained in this presentation constitutes investment, legal, tax or other advice. This overview of investment does not purport to be all inclusive or to contain all information which its recipients may require in order to make an informed assessment of the Company’s prospects. The Company's statutory results are prepared in accordance with International Financial Reporting Standards (“IFRS”). This presentation also includes certain non-IFRS measures in presenting the Company’s results. Any additional financial information in this presentation which is not included in the Company’s 30 June 2018 Financial Statements was not subject to independent audit or review. Investors should be aware that certain financial data included in this presentation is “non-IFRS financial information” under ASIC Regulatory Guide 230: “Disclosing non-IFRS financial information” published by ASIC and may also be “non-GAAP financial information” within the meaning given under Regulation G of the U.S. Securities Exchange Act of 1934, as amended. Non-IFRS financial information does not have a standardised meaning prescribed by Australian Accounting Standards (“AAS”). Accordingly, the non-IFRS financial information in this presentation: (i) may not be comparable to similarly titled measures presented by other entities; (ii) should not be construed as an alternative to other financial measures determined in accordance with AAS; and (iii) is not a measure of performance, liquidity or value under the IFRS. Investors are cautioned, therefore, not to place undue reliance on any non-IFRS financial information included in this presentation. To the maximum extent permitted by law, the Company and its advisers make no representation and give no assurance, guarantee or warranty, express or implied, as to, and take no responsibility and assume no liability for, the authenticity, validity, accuracy, suitability or completeness of, or any errors in or omissions, from any information, statement or opinion contained in this presentation. All values are expressed in Australian currency unless otherwise stated. This presentation is not for release to US wire services or distribution in the United States or any country where it may be unlawful. See "International Offer Restrictions". DISCLAIMER 9
More from Star Combo Pharma
Join Listcorp to create a personalised news feed, follow your favourite companies, save useful news, and more.